Clinical Trial Detail

NCT ID NCT04042701
Title DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Daiichi Sankyo, Inc.
Indications

lung non-small cell carcinoma

Her2-receptor positive breast cancer

Therapies

Pembrolizumab + Trastuzumab deruxtecan

Age Groups: adult senior

Additional content available in CKB BOOST